Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

References

• LowenfelsABMaisonneuvePEpidemiology and risk factors for pancreatic cancerBest Pract Res Clin Gastroenterol20092019720916549324
   PubMedGoogle Scholar
• SiegelRMaJZouZJemalACancer statistics. 2014CA Cancer J Clin20146492924399786
   PubMed Web of Science ®Google Scholar
• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer2013491374140323485231
   PubMed Web of Science ®Google Scholar
• Bond-SmithGBangaNHammondTMImberCJPancreatic adenocarcinomaBMJ2012344e247622592847
   PubMed Web of Science ®Google Scholar
• CascinuSGrazianoFCatalanoGChemotherapy for advanced pancreatic cancer: it may no longer be ignoredAnn Oncol19991010510910076729
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol199715240324139196156
   PubMed Web of Science ®Google Scholar
• BerlinJDCatalanoPThomasJPKuglerJWHallerDGBensonAB3rdPhase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297J Clin Oncol2002203270327512149301
   PubMed Web of Science ®Google Scholar
• Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol2004223776378315365074
   PubMed Web of Science ®Google Scholar
• OettleHRichardsDRamanathanRKA phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerAnn Oncol2005161639164516087696
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol2005233509351615908661
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol2006244441444716983112
   PubMed Web of Science ®Google Scholar
• HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJ Clin Oncol2006243946395216921047
   PubMed Web of Science ®Google Scholar
• ScheithauerWSchüllBUlrich-PurHBiweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trialAnn Oncol2003149710412488300
   PubMed Web of Science ®Google Scholar
• ColucciGGiulianiFGebbiaVGemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia MeridionaleCancer20029490291011920457
   PubMed Web of Science ®Google Scholar
• KindlerHLNiedzwieckiDHollisDGemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)J Clin Oncol2010283617362220606091
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol2007251960196617452677
   PubMed Web of Science ®Google Scholar
• DragovichTHubermanMVon HoffDDErlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trialCancer Chemoth Pharm200760295303
   PubMed Web of Science ®Google Scholar
• ArdavanisAKountourakisPKaragiannisADoufexisDTzovarasAARigatosGBiweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancerAnticancer Res2009295211521720044638
   PubMed Web of Science ®Google Scholar
• BengalaCSternieriRMalavasiNPhase II trial of erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer (advanced pancreatic cancer)2009ASCO Gastrointestinal Cancers Symposium [abstract number: 156] Available from: http://meetinglibrary.asco.org/content/10332-63Accessed January 28, 2009
   Google Scholar
• Van CutsemEVervenneWLBennounaJPhase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol2009272231223719307500
   PubMed Web of Science ®Google Scholar
• ChengYJBaiCMZhangZJEfficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancerZhongguo Yi Xue Ke Xue Yuan Xue Bao20103242142320868602
   PubMedGoogle Scholar
• MilellaMVaccaroVSperdutiIPhase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC)2010ASCO Annual Meeting [abstract number: e14565] Available from: http://meetinglibrary.asco.org/content/51951-74Accessed June 4, 2010
   Google Scholar
• OkusakaTFuruseJFunakoshiAPhase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancerCancer Sci201110242543121175992
   PubMed Web of Science ®Google Scholar
• BoeckSVehling-KaiserUWaldschmidtDErlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the “Arbeitsgemeinschaft Internistische Onkologie.”Anticancer Drugs2010219410019770635
   PubMed Web of Science ®Google Scholar
• StuebsPHabermannPZierauKFirst-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: a multivariate matched pair analysis2010ASCO Annual Meeting [abstract number: e14572] Available from: http://meetinglibrary.asco.org/content/52331-74Accessed: June 4 2010
   Google Scholar
• KimGPFosterNRSalimMRandomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma2011ASCO Gastrointestinal Cancers Symposium [abstract number: 238] Available from: http://meetinglibrary.asco.org/content/71370-103Accessed January 20, 2011
   Google Scholar
• FeliuJBorregaPLeónAPhase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancerCancer Chemother Pharmacol20116721522120927525
   PubMed Web of Science ®Google Scholar
• LlarenaMAManeJLopez-VivancoGGemcitabine (G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (advanced pancreatic cancer)2011ASCO Gastrointestinal Cancers Symposium [abstract number: 304] Available from: http://meetinglibrary.asco.org/content/71207-103Accessed January 20, 2011
   Google Scholar
• ArandaEManzanoJLRiveraFPhase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)Ann Oncol2012231919192522156621
   PubMed Web of Science ®Google Scholar
• JeonEKWonHSKoYHComparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancerJ Cancer Res Clin Oncol20121381625163022614154
   PubMed Web of Science ®Google Scholar
• ModianoMKeoghGPMangesRApricot-P: a randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas2012ASCO Gastrointestinal Cancers Symposium [abstract number: 253] Available from: http://meetinglibrary.asco.org/content/87740-115Accessed January 19, 2012
   Google Scholar
• ParkSChungMJParkJYPhase II trial of erlotinib plus gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors for chemotherapeutic responseGut Liver2013761161524073321
   PubMed Web of Science ®Google Scholar
• Van CutsemELiCPNowaraEDose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyBJC20141112067207525247318
   PubMed Web of Science ®Google Scholar
• LimJYChoJHLeeSJLeeDKYoonDSChoJYGemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancerCancer Res Treat20154726627325327494
   PubMed Web of Science ®Google Scholar
• WilminkJKordesSZwindermanKMathotRPuntCJARichelDA phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced or metastatic pancreatic cancer2014ASCO Annual Meeting [abstract number: 4021] Available from: http://meetinglibrary.asco.org/content/129089-144Accessed May 30, 2014
   Google Scholar
• PhilipPAGoldmanBRamanathanRKDual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Cancer20141202980298525041791
   PubMed Web of Science ®Google Scholar
• Diaz BeveridgeRAlcoleaVAparicioJManagement of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practiceJOP201415192424413779
   PubMedGoogle Scholar
• SemradTBarziALenzHJPharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker resultsInt J Clin Oncol20152051852425091263
   PubMed Web of Science ®Google Scholar
• BenavidesMPlazasJGGuillenCGemcitabine (G)/erlotinib (E) versus gemcitabine/erlotinib/capecitabine in the first line treatment of patients with metastatic pancreatic cancer (mPC): efficacy and safety results of a phase IIb randomized study from the Spanish TTD2014ASCO Annual Meeting [abstract number: 4122] Available from: http://meetinglibrary.asco.org/content/129070-144Accessed May 30, 2014
   Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials198671771883802833
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
   PubMed Web of Science ®Google Scholar
• HardyRJThompsonSGDetecting and describing heterogeneity in meta-analysisStat Med1998178418569595615
   PubMed Web of Science ®Google Scholar
• NCCN guidelines for pancreatic cancer Available from: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed January 30, 2016
   Google Scholar
• BareschinoMASchettinoCTroianiTMartinelliEMorgilloFCiardielloFErlotinib in cancer treatmentAnn Oncol200718Suppl 6vi35vi4117591829
   PubMedGoogle Scholar
• DurkinAJBloomstonPMRosemurgyASDefining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitroAm J Surg200318643143614599602
   PubMed Web of Science ®Google Scholar
• FjällskogMLLejonklouMHObergKEErikssonBKJansonETExpression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumorsClin Cancer Res200391469147312684421
   PubMed Web of Science ®Google Scholar
• XiongHQMolecular targeting therapy for pancreatic cancerCancer Chemother Pharmacol200454Suppl 1S69S7715316751
   PubMedGoogle Scholar
• UedaSOgataSTsudaHThe correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinomaPancreas200429e1e815211117
   PubMed Web of Science ®Google Scholar
• PhilipPABenedettiJCorlessCLPhase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205J Clin Oncol2010283605361020606093
   PubMed Web of Science ®Google Scholar
• CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJ Clin Oncol2009275513551819858379
   PubMed Web of Science ®Google Scholar